Lilly to invest $1 billion+ in new contract manufacturing in India

Investment to expand manufacturing and global medicine supply capacity

Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial

FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

Experts highlight critical link between mental well-being and cardiovascular health

Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Apollo signs agreement to manage internal security force hospital in Iraq

The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel